To invite Dr. Howick to be a speaker at your event please send an email to email@example.com
26 January 2018. ‘Doctors as healers’ (Grand rounds talk). University of British Columbia, Canada.
3 June 2018. ‘Decision-Oriented Evidence: Uncertainties And Opportunities’. Health Technology Assessment international Conference. Vancouver, Canada.
17 November 2017. ‘Ethics, Nocebos, and informed consent’. Cardiff University https://twitter.com/CTRCardiffUni/status/927533008898453504
21 July 2017. “Placebo is an ethically endorsed treatment and not deceitful quackery” (Debate against Professor David Healy). Royal Society of Medicine. London, UK.
11 May 2017. “The emerging discipline of empirical philosophy and why it is needed to inform evidence-based policy”. Evidence-Based Policy: One-Day Workshop. Copenhagen, Denmark.
20 April 2017. “The need for empirical philosophy: evidence from three case-studies”. Too Much Medicine. Oxford, UK.
13 April 2017. “Why it is ethical to exploit placebo effects in clinical practice”. Sherborne Science Café. Sherborne, UK.
2-4 April 2017 (Leiden, The Netherlands). 1st official Society for Interdisciplinary Placebo Studies (SIPS) conference. “Ethical aspects and challenges of trial design in placebo research”
3-4 October 2016. Masterclass “Angelo Ferro” (Padova, Italy). “Etica, sport e benessere mentale” [Ethics, Sport, and Psychological Wellbeing]
8 September 2016. Royal College of Chiropractors Continuing Professional Development Event. “The Difficulty in designing placebos for complex treatments like chiropractic, and why the mind/body separation doesn’t make sense”
21 June 2016 (London, UK). iWGC (I Want Great Care) Symposium 2016. How empathetic care improves patient outcomes, patient satisfaction, reduces medico-legal risk, and improves job satisfaction.
10 November 2015. “Why it is ethical to prescribe placebos in Clinical Practice”. Oxford Café Scientifique. Oxford, UK.
14 October 2015. “Why it is ethical to prescribe placebos in Clinical Practice”. Bath Science Café. Bath, UK.
13 May 2015. “Mindfulness for Leadership”. Said Business School. Oxford, UK.
21 October 2014. “Defending a definition of placebo controls”. Harvard University Placebo Studies Programme. Boston, USA.
6 May 2012. “Evidence-Based Neurophysiological Monitoring” (Presidential Address to the American Society of Neurophysiological Monitoring). Salt Lake City, Utah (USA).
Selected Peer Reviewed Conferences and Invited Talks
24th May 2016. (Oxford, UK) Better Value Musculoskeletal Care Interventions to help clinicians drop ineffective treatments. ? Dr Jeremy Howick
20 January 2016. “Exploring the epistemological role of mechanism in medical treatment discovery by evaluating the meta-research data” University of Oslo Science Studies Colloquium. Oslo, Norway.
20 March 2016 “Your Inner Doctor” MISTY Festival. Montreal, Canada.
20 April 2016. “Evidential support for the view that we need to think about mechanisms: necessary or a search in the dark? Munich Center for Mathematical Philosophy. Ludwig-Maximilians-Universität München. Munich, Germany.
7 December 2015. “Why placebos are better than amphetamines for boys who can’t down in school” Ludwig-Maxmillians Universität München Institute of Medical Psychology, Munich, Germany.
13 April 2015 Evidence Live “A new generation of bias in EBM”
25 March 2015. “Questioning the Usefulness of Basic Science Research for Generating Clinically Useful Treatments”. McGill University, Montreal.
25 March 2015. “The Need For More Evidence In Ethical Debates”. Universite de Montreal. Montreal, Canada.
18 March 2015. “Applying Evidence-Based Medicine to Cancer Trials”. Cancer Research UK. London, UK.
13 November 2014. “Bias in Animal Studies”. National Institutes for Health Research, Washington DC, USA
6-9 November 2014. “What Counts as a Placebo is Relative to a Target Disorder and Therapeutic Theory: Defending a Modified Version of Grünbaum’s Scheme”. Philosophy of Science Association Biennial Meeting, Chicago, USA.
28 February 2014. “The need to define placebos to have rational policies about ethical placebo use in clinical trials and practice: defending a modified version of Grünbam’s scheme” University of California, San Diego (UCSD). La Jolla (US).
7 February 2014. “A justification for the 2011 Oxford Centre for Evidence-Based Medicine Levels of Evidence” European Urology Association (EUA). London (UK).
7 October 2013. “Evidence according to the Oxford Centre for Evidence-Based Medicine: where it is going next” Danish Society for Obstetrics and Gynaecology (DSOG). Copenhagen (Denmark).
5 April 2013. “Evidence-Based Medicine” (Inaugural lecture for the Lithuanian Centre for Evidence-Based Medicine). Vilnius (Lithuania).
31 January 2012. “The importance of conceptualizing ‘placebos’ when attempting to empirically measure ‘placebo’ effects”. King’s College London.
13 December 2011. “Problems with Using Mechanisms to Solve the Problem of External Validity: Reply to Cartwright”. Philosophy of Epidemiology Conference.
9 November 2011. “Using Mechanisms to Solve the Problem of Applying Average Trial Results”. Zentrum Geschichte des Wissens, Zurich, Switzerland.
3 November 2011. “Problems with Using Mechanisms to Solve the Problem of External Validity: Reply to Cartwright”. Philosophy of Medicine Roundtable. University of the Basque Country, Spain.
25 October 2011. “Randomization and Blinding in Animal Experiments: a Call to Arms for Blinding Mice” (poster presentation). Evidence 2011. London, United Kingdom
12 February 2010. “What Evidence do Experts Provide?” University College London, United Kingdom.
15 April 2010. “Placebo controls: problematic and misleading ‘baseline measure of effectiveness’”. University of Bristol, United Kingdom.
12 October 2009. “Questioning the methodological superiority of ‘placebo’ over ‘active’ controlled trials”. Cochrane Colloquium. Singapore.
24 September 2009. “What on Earth was Medicine Based on Before Evidence-Based Medicine?” Descartes Centre, University of Utrecht, Netherlands.
10 September 2009. “Defining a Role for Mechanistic Reasoning in Evidence-Based Medicine”. Mechanisms and Causality in the Sciences. University of Kent, Canterbury, UK.
6-9 November 2008. “Double-Masking: The Benefits and Risks of Being in the Dark”. Philosophy of Science Association Biennial Meeting, Pittsburgh, USA.
7 March 2008. “Double-Masking: The Benefits and Risks of Being in the Dark” Society for Academic Primary Care. Warwick Medical School, Warwick.
19-20 June 2006. “Evidence from Above: Allowing Background Knowledge and Preventing Prejudice”. Contingency and Dissent Workshop. LSE.
29-31 May 2006. “Placebo Controls: Epistemic Virtue or Vice?” International Conference of the Canadian Society for the History and Philosophy of Science Toronto, Canada.
12 April 2006. (Given in Spanish) “The Assumption of Additivity in Randomized Controlled Trials (RCTs)”. First Annual Conference in the Philosophy of Medicine. Computense, Madrid, Spain.
2 June 2006. “Placebo Controls: Epistemic Virtue or Vice” International Conference on Philosophy, Athens Institute for Education and Research, Greece.
18 November 2005. “Placebo Controls: Epistemic Virtue or Vice”. Philosophy of Medicine Roundtable, University of Alabama, Birmingham, USA.
10 March 2005. “The Role of Randomization: A Response to John Worrall’s “Why Randomize?”” Experimental Philosophy Laboratory (EPL). University of California, San Diego, USA (http://mind.ucsd.edu/epl/).